ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

National Cancer Centre, Singapore

Status and phase: Unknown; Phase 1

Conditions: Solid Tumors

Treatments: Drug: ASLAN001+ CAPOX (Oxaliplatin, capecitabine); Drug: ASLAN001 + mFolfox6 (5-FU, leucovorin)

Study type: Interventional

Funder types: Other

Identifiers

NCT02435927

ASLAN001-002SG

Details and patient eligibility

About

This is a Phase I, open-label, dose escalation study of ASLAN001 given in combination with CAPOX or mFolfox6, in patients with metastatic solid tumours, whom are suitable to receive CAPOX or mFolfox6, or with tumours that have dysregulated EGFR or HER2 signaling.

Full description

The study will use standard 3+3 design to determine the MTD (maximum tolerated dose) of ASLAN001 in combination with fixed dose of Oxaliplatin/Capecitabine (CAPOX) or 5-FU/leucovorin (mFolfox6).

MTD of ASLAN001 in combination with CAPOX will first be determined followed by the combination with mFolfox6.

The recommended Phase II dose will be the highest dose of the combination therapy that is considered to be tolerated in 6 patients.

Enrollment: 60 estimated patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with metastatic solid tumours eligible for treatment with oxaliplatin in combination with capecitabine / 5-FU (fluorouracil) and leucovorin or who progressed following standard therapy or patients with EGFR (epidermal growth factor receptor ) or HER2 dysregulated tumours.

2. Patients with a partial gastrectomy may be allowed to participate in the study as long as they can take oral medications and meet all other inclusion/exclusion criteria.

3. Eastern Cooperative Oncology Group performance status of 0 or 1.

4. Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days prior to enrolment:

   • Hematological function, as follows: Absolute neutrophil count ≥ 1.5 x 109/L. Platelet count ≥ 100 x 109/L. Hemoglobin ≥ 9 g/dL.

   • Coagulation function, as follows: Prothrombin time and activated partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN) per institutional laboratory normal range.

   • Renal function, as follows: Creatinine clearance ≥ 50 mL/min as calculated by Cockcroft-Gault formula.

   • Hepatic function, as follows: Total bilirubin ≤ 1.5 x ULN. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present).

5. Patients undergoing mandatory biopsy in dose expansion of a non-DLT cohort should have any of the following:

   • known HER2 or EGFR dysregulation
   • Patients with T790M mutation will be excluded.
   • Co-expression of HER2 and EGFR

6. Archival tumour sample is available for molecular profiling, unless undergoing tumour biopsy as part of the trial.

Exclusion criteria

1. Patients with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy.

2. Patients receiving proton pump inhibitors or H2 antagonists for established, symptomatic gastro duodenal ulceration or gastroesophageal reflux disease. H2 antagonist can be prescribed after DLT (dose-limiting toxicity) period (the first 2 cycles) at the discretion of the investigator.

3. Patients with unresolved toxicities of grade 2 or more from prior anti-cancer therapies excluding alopecia.

4. Untreated or symptomatic central nervous system metastases. Patients with treated brain metastases stable for 3 months are eligible to enroll.

5. Major surgical procedures within 28 days prior to enrolment.

6. Clinically significant cardiovascular diseases that are symptomatic or uncontrolled.

7. Known active infection for human immunodeficiency virus, hepatitis B and C.

8. Pregnant or breast-feeding females.

9. Treatment with any of the following anti-cancer therapies prior to the first dose of study drugs within the stated timeframes

   • Cyclical chemotherapy within a period of time that is shorter than the cycle length used for that treatment. Exception for weekly chemotherapy regimens, where a minimum of 2 week washout from the last dose is required.
   • Biological therapy (e.g., antibodies) within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks, whichever is shorter, prior to starting study drug
   • Continuous or intermittent small molecule therapeutics within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug
   • Any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shortest) prior to starting study drug
   • Wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug
   • Previous combination therapy with xeloda and oxaliplatin within 6 months of study treatment.
   • Previous combination therapy with Oxaliplatin, 5-FU and Leucovorin (mFolfox6) within 6 months of study treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

ASLAN001 + CAPOX

Experimental group

Description:

ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks

Treatment:

Drug: ASLAN001+ CAPOX (Oxaliplatin, capecitabine)

ASLAN001 + mFolfox6

Experimental group

Description:

ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks

Treatment:

Drug: ASLAN001 + mFolfox6 (5-FU, leucovorin)